190 related articles for article (PubMed ID: 37436885)
21. Bridging genomics and phenomics of gastric carcinoma.
Cho J; Ahn S; Son DS; Kim NK; Lee KW; Kim S; Lee J; Park SH; Park JO; Kang WK; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Int J Cancer; 2019 Nov; 145(9):2407-2417. PubMed ID: 30801717
[TBL] [Abstract][Full Text] [Related]
22. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract][Full Text] [Related]
23. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine.
Nagahashi M; Wakai T; Shimada Y; Ichikawa H; Kameyama H; Kobayashi T; Sakata J; Yagi R; Sato N; Kitagawa Y; Uetake H; Yoshida K; Oki E; Kudo SE; Izutsu H; Kodama K; Nakada M; Tse J; Russell M; Heyer J; Powers W; Sun R; Ring JE; Takabe K; Protopopov A; Ling Y; Okuda S; Lyle S
Genome Med; 2016 Dec; 8(1):136. PubMed ID: 28007036
[TBL] [Abstract][Full Text] [Related]
24. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
[TBL] [Abstract][Full Text] [Related]
25. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
27. Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.
Jia F; Teer JK; Knepper TC; Lee JK; Zhou HH; He YJ; McLeod HL
Mol Diagn Ther; 2017 Apr; 21(2):179-185. PubMed ID: 28039579
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
29. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
30. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
31. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
[TBL] [Abstract][Full Text] [Related]
32. Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.
Ge S; Li B; Li Y; Li Z; Liu Z; Chen Z; Wu J; Gao J; Shen L
Am J Cancer Res; 2017; 7(7):1540-1553. PubMed ID: 28744403
[TBL] [Abstract][Full Text] [Related]
33. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
Yuan J; Kensler KH; Hu Z; Zhang Y; Zhang T; Jiang J; Xu M; Pan Y; Long M; Montone KT; Tanyi JL; Fan Y; Zhang R; Hu X; Rebbeck TR; Zhang L
PLoS Genet; 2020 Feb; 16(2):e1008641. PubMed ID: 32059012
[TBL] [Abstract][Full Text] [Related]
34. Druggable gene alterations in Japanese patients with rare malignancy.
Ohmoto A; Hayashi N; Fukada I; Yamazaki M; Yunokawa M; Kasuga A; Shinozaki E; Ueki A; Tonooka A; Takeuchi K; Mori S; Kiyotani K; Takahashi S
Neoplasia; 2022 Nov; 33():100834. PubMed ID: 36088851
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica.
Liu Z; Hong LL; Zheng JS; Ling ZN; Zhang ZL; Qi YN; Zhang XY; Zhu TY; Wang JL; Han J; Chen XL; Yu QM; Wang S; Li P; Ling ZQ
Gastric Cancer; 2023 Mar; 26(2):203-219. PubMed ID: 36450891
[TBL] [Abstract][Full Text] [Related]
36. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
[TBL] [Abstract][Full Text] [Related]
37. Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
Gleeson FC; Kipp BR; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Graham RP; Lazaridis KN; Henry MR; Levy MJ
Gastrointest Endosc; 2015 Sep; 82(3):550-6.e1. PubMed ID: 25887718
[TBL] [Abstract][Full Text] [Related]
38. A Novel Microbiome Signature in Gastric Cancer: A Two Independent Cohort Retrospective Analysis.
Abate M; Vos E; Gonen M; Janjigian YY; Schattner M; Laszkowska M; Tang L; Maron SB; Coit DG; Vardhana S; Vanderbilt C; Strong VE
Ann Surg; 2022 Oct; 276(4):605-615. PubMed ID: 35822725
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
Wang X; Beharry A; Sheffield BS; Cheema PK
Oncologist; 2023 Jun; 28(6):474-478. PubMed ID: 36933203
[TBL] [Abstract][Full Text] [Related]
40. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
